MHC class I H2-Kb negatively regulates neural progenitor cell proliferation by inhibiting FGFR signaling.

Proteins of the major histocompatibility complex class I (MHC I), predominantly known for antigen presentation in the immune system, have recently been shown to be necessary for developmental neural refinement and adult synaptic plasticity. However, their roles in nonneuronal cell populations in the brain remain largely unexplored. Here, we identify classical MHC I molecule H2-Kb as a negative regulator of proliferation in neural stem and progenitor cells (NSPCs). Using genetic knockout mouse models and in vivo viral-mediated RNA interference (RNAi) and overexpression, we delineate a role for H2-Kb in negatively regulating NSPC proliferation and adult hippocampal neurogenesis. Transcriptomic analysis of H2-Kb knockout NSPCs, in combination with in vitro RNAi, overexpression, and pharmacological approaches, further revealed that H2-Kb inhibits cell proliferation by dampening signaling pathways downstream of fibroblast growth factor receptor 1 (Fgfr1). These findings identify H2-Kb as a critical regulator of cell proliferation through the modulation of growth factor signaling.

Introduction

Major histocompatibility class I (MHC I) proteins are most well known for their role in antigen presentation and immunological surveillance in the adaptive immune system [1]. More recently, in the central nervous system (CNS), immune components—such as complement, cytokines, and MHC I molecules—have been demonstrated to play noncanonical roles in the developing and adult brain [2-5]. Specifically, classical MHC I molecules, H2-Kb and H2-Db, have been shown to negatively regulate visual system plasticity, neurite outgrowth, synapse density, and synaptic strength [6-11]. Notwithstanding, their role in regulating cellular functions beyond mature neuronal cell types in the brain remain largely unexplored.

Neural stem cells (NSCs), capable of producing functional neurons during embryonic and perinatal development as well as partially throughout life, represent a unique cell type critical in the formation of the CNS and potentially amenable to regenerative biology [12,13]. NSCs of the dentate gyrus (DG) reside in a specialized niche that supports their maintenance, proliferation, and differentiation into excitatory granule cells that integrate into hippocampal circuitry and confer plasticity [14]. This fine-tuned process is responsive to modulation by cell-intrinsic mechanisms, including transcription factors such as Sox2, TLX, and FoxOs, epigenetic factors like Tet2, posttranslational modifiers like Ogt, as well as changes to the neurogenic niche and systemic environment through manipulations such as exercise and exposure to young blood [15-21]. Importantly, neurogenesis can be regulated by immune system components such as cytokines, Toll-like receptors, and T cells [22-25]. One such factor, β2-microglobulin, the noncovalently associated subunit of the MHC I complex, has been implicated as a pro-aging systemic factor inhibiting neurogenesis [26]. However, the role of MHC I molecules themselves in regulating neural stem and progenitor cell (NSPC) function has yet to be investigated. Given the roles of MHC I molecules in negatively regulating neuronal processes and the susceptibility of NSPCs to immune influence, we sought to investigate the role of classical MHC I molecules, H2-Kb and H2-Db, in NSPC function.

In this study, we identify classical MHC I molecule H2-Kb individually as a negative regulator of NSPC proliferation and hippocampal neurogenesis. Using a combination of in vivo genetic mouse models, viral-mediated in vivo RNA interference (RNAi) and overexpression, and in vitro NSPC functional assays, we identify H2-Kb as a negative regulator of NSPC proliferation and adult hippocampal neurogenesis. Using RNA-sequencing (RNA-seq) transcriptomic analysis and in vitro RNAi, overexpression, and pharmacological inhibition, we provide evidence that loss of H2-Kb in NSPCs enhances proliferation through fibroblast growth factor receptor 1 (Fgfr1) signaling pathways. Together, these data delineate a noncanonical role for a specific individual MHC I molecule, H2-Kb, in NSPC function.

Results

Loss of H2-Kb, and not H2-Db, increases neurogenesis in the adult hippocampus

Previous studies have ascribed H2-Kb and H2-Db with predominantly analogous functions in the brain [3]. Given the diversity of this family of molecules, we explored potential differential roles each individual classical MHC I molecule may play in NSPC function. To test this possibility, we first analyzed a publicly available dataset describing the transcriptomic dynamics of early phase adult hippocampal neurogenesis at the single-cell level [27]. Single-cell gene expression profiles were generated for Nestin-positive cells and their immediate progeny, with each cell bioinformatically assigned along a continuous trajectory from quiescent NSC activation to initiation of neurogenesis. Specifically, we divided the neurogenic lineage into an early time point (T1) where NSCs express glial fibrillary acidic protein (GFAP), and a later time point (T2) where differentiating intermediate neural progenitors begin to express T-box brain protein 2 (Tbr2) (Figs ). Trend lines of H2-K1, H2-D1, and the proliferation marker Ki67 expression were fitted along this neurogenic trajectory (). Interestingly, as Ki67 expression increased H2-K1 expression decreased, while H2-D1 expression remained static (). Correspondingly, the frequency of cells expressing H2-K1 was significantly lower during T2 compared to T1, while no changes were observed for H2-D1, consistent with the housekeeping gene Gapdh (). These bioinformatics data suggest a potential role for H2-Kb in regulating NSPC function during proliferative phase of adult neurogenesis.

To investigate the potential exclusivity of H2-Kb, and not H2-Db, in regulating hippocampal neurogenesis in vivo, we utilized genetic mouse models in which H2-K1 (K−/−) or H2-D1 (D−/−) are individually excised (). Absence of H2-K1 or H2-D1 mRNA expression was confirmed by qPCR (). Cell proliferation was assessed by short-term 5-ethynyl-2′-deoxyuridine (EdU) labeling, and neurogenesis was examined by immunohistochemistry in adult K−/−, D−/−, and wild-type (WT) mice. The number of Nestin-positive radial glial-like stem cells was not different between genotypes (). However, absence of H2-Kb, but not H2-Db, resulted in significantly more EdU-positive proliferating cells and Doublecortin (Dcx)-positive neuroblasts in the DG compared to WT controls (). Additionally, we assessed neuronal differentiation and survival using a long-term 5-bromo-2′-deoxyuridine (BrdU) incorporation paradigm, in which postmigratory differentiated neurons coexpress both BrdU and the mature neuronal marker neuronal nuclei (NeuN). The number of BrdU/NeuN double-positive differentiated mature neurons was increased in K−/−, but not D−/−, mice compared to WT controls (). Given H2-Kb and H2-Db molecules are critical for immune cell development and function, we assessed microglia in the DG and detected no differences in the number of microglia expressing ionized calcium-binding adapter molecule 1 (Iba1) or the percent of microglia coexpressing the activation marker cluster of differentiation 68 (CD68) in K−/− or D−/− mice compared to WT controls (). No differences in GFAP-positive astrocytes or overall DG size were observed between genotypes (). Similar results for adult neurogenesis and microglia activation were observed in a genetic knockout mouse model in which H2-K1 and H2-D1 are concomitantly excised (KD−/−; ).

H2-Kb overexpression decreases NSPC proliferation and impairs adult hippocampal neurogenesis.

Ten-week-old adult WT mice were stereotaxically injected with lentiviruses expressing H2-Kb (OE-K), H2-Db (OE-D), or GFP control (OE-Ctrl) under the Nestin promoter (A). (B) Representative fields of Nestin-GFP expressing cells (left panel), EdU+ short-term proliferating cells, Dcx+ neuroblasts (middle panel), and adult-born neurons coexpressing BrdU and NeuN (right panel) in the DG. (C) Quantification of EdU+, Dcx+, and BrdU+/NeuN+ cells in the DG. n = 8–15 animals/group (3–4 sections/animal); scale bars: 50 μm. (D) WT adult NSPC were infected with OE-K, OE-D, and OE-Ctrl lentiviruses and grown under self-renewal conditions. Representative images (left panels) and quantification (right panel) of the percentage of EdU+ proliferating NSPCs after 6 hours of EdU treatment. n = 8 replicates/group; scale bars: 100 μm. (E) WT adult NSPC were infected with sh-K or sh-Ctrl, followed by infection with OE-K, OE-D, or OE-Ctrl lentiviruses. Representative images (E, left panel) and quantification (E, right panel) of EdU+ proliferating NSPCs after 6 hours of EdU treatment. n = 6 replicates/group; scale bar: 100 μm. Data represented as mean ± SEM. One-way ANOVA with Dunnett’s multiple comparisons test; *p < 0.05, ***p < 0.001. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). BrdU, 5-bromo-2′-deoxyuridine; Dcx, Doublecortin; DG, dentate gyrus; EdU, 5-ethynyl-2′-deoxyuridine; GFP, green fluorescent protein; NeuN, neuronal nuclei; n.s., not significant; NSPC, neural stem and progenitor cell; WT, wild-type.

To complement the genetic mutant model and circumvent potential developmental effects of a constitutive knockout, we next used an in vivo viral-mediated RNAi approach. We generated lentiviral constructs encoding short hairpin RNA (shRNA) sequences selectively targeting either H2-Kb (sh-K) or H2-Db (sh-D) mRNA, as well as targeting luciferase as a control (sh-Ctrl). Knockdown of H2-Kb and H2-Db expression was confirmed by qPCR (). Adult WT mice were stereotaxically injected into the right DG with either sh-K or sh-D and into the left contralateral DG with sh-Ctrl (). Cell proliferation was assessed by short-term EdU labeling, and neuronal differentiation was assessed by long-term BrdU labeling. Local and temporally controlled abrogation of H2-Kb in the adult DG resulted in an increase in the number of EdU-positive proliferating cells, Dcx-positive neuroblasts, and BrdU/NeuN double-positive mature differentiated neurons compared to the contralateral control (). No differences were detected following abrogation of H2-Db in the adult DG compared to control conditions (). Together, these data identify H2-Kb individually as a negative regulator of cell proliferation and neurogenesis in the adult hippocampus.

Absence of H2-Kb in NSPCs increases proliferation, in part, by altering cell cycle dynamics

Having observed the involvement of H2-Kb in regulating adult neurogenesis in vivo, and to circumvent the lack of cell-type specificity inherent in using constitutive knockout or viral-mediated RNAi in vivo models, we next investigated the functional role of H2-Kb in NSPC proliferation in vitro. We subdissected hippocampi from K−/−, D−/−, and WT mice and cultured primary postnatal NSPCs following an established protocol [28]. K−/−, D−/−, and WT NSPCs were cultured under self-renewal conditions and treated with EdU. We detected a significant increase in the percentage of EdU-positive proliferating cells in K−/− compared to WT NSPCs (), while no differences were observed in D−/− NSPCs (. Under differentiation conditions in vitro, no differences in the percentage of neurons and astrocytes were detected between genotypes (), suggesting a role for H2-Kb in specifically regulating the proliferative process in NSPCs in vitro. These results were corroborated by in vitro studies in cultured WT postnatal and adult NSPCs, where acute abrogation of H2-Kb, but not H2-Db, expression by RNAi resulted in a significant increase in EdU-positive proliferating cells compared to control conditions (). No differences in differentiation were observed following H2-Kb or H2-Db abrogation (). Increased NSPC proliferation was also observed in WT postnatal and adult NSPCs in which H2-Kb and H2-Db expression is concomitantly decreased (). These in vitro data identify H2-Kb as a negative regulator of NSPC proliferation.

To further examine the role of H2-Kb in regulating adult NSCP proliferation, we made use of the publicly available dataset described above (). We scored each single cell analyzed for expression of signatures indicative of the G1/S or G2/M phases of the cell cycle (as described in Tirosh and colleagues [29]) and subsequently identified each cell as either positive or negative for H2-K1 expression (). We found that the percentage of cycling cells to be lower in H2-K1-positive cells (5.6%) versus H2-K1-negative cells (24.4%), suggesting that adult NSCs and their immediate progeny are more likely to be noncycling when enriched for H2-K1 (). These bioinformatics data provide evidence that H2-Kb potentially regulates NSPC proliferation by impacting the cell cycle.

Increased hippocampal NSPC proliferation is a phenomenon known to occur under certain stimuli; in the case of seizures, a shortened cell cycle length is the cellular mechanism underlying the enhancements in cell proliferation [30]. Correspondingly, we examined if similar changes occurred in cell cycle dynamics of NSPCs lacking H2-Kb. Primary hippocampal NSPCs isolated from K−/− and WT mice were cultured under self-renewal conditions and were subsequently treated with EdU at 2-hour intervals over a 20-hour period. Absence of H2-Kb resulted in an increase in the ratio of proliferating cells to the total number of cells in the population, corresponding to the growth fraction (GF; ). Furthermore, we detected a decrease in both the length of the S-phase (Ts) and length of the cell cycle (Tc; ), calculated as described in Ponti and colleagues [31]. These in vitro data indicate that NSPCs lacking H2-Kb exhibit increased proliferation, in part, due to an acceleration of cell cycle progression.

Overexpression of H2-Kb, and not H2-Db, in neural stem cells decreases adult hippocampal neurogenesis and impairs NSPC proliferation

To complement our loss of function studies, we investigated the effect of increasing H2-Kb expression in adult NSCs. We used a cell-type specific in vivo viral-mediated overexpression approach, in which we generated lentiviral constructs encoding either H2-Kb (OE-K), H2-Db (OE-D), or green fluorescent protein (GFP) as a control (OE-ctrl) under the control of the Nestin promoter. Overexpression of H2-K1 and H2-D1 expression was confirmed by qPCR (). Adult WT mice were stereotaxically injected into the right DG with either OE-K or OE-D and into the left contralateral DG with OE-ctrl (). Cell proliferation was assessed by short-term EdU labeling, and neuronal differentiation was assessed by long-term BrdU labeling. Increased expression of H2-Kb in adult NSCs resulted in a decrease in the number of EdU-positive proliferating cells, Dcx-positive neuroblasts, and BrdU/NeuN double-positive mature differentiated neurons compared to the contralateral control (). No differences were detected following overexpression of H2-Db in adult NSCs compared to control conditions ().

We next investigated the effect of increased H2-Kb expression on adult NSPC proliferation in vitro. WT adult NSPCs were infected with OE-K, OE-D, or OE-ctrl lentivirus and treated with EdU. Overexpression of H2-Kb, but not H2-Db, resulted in a significant decrease in EdU-positive proliferating cells compared to control (). To further delineate the role of H2-Kb, we examined whether the effects of abrogating H2-Kb on NSPC proliferation could be rescued by overexpressing either H2-Kb or H2-Db. WT adult NSPC were infected with sh-K lentivirus in combination with OE-K, OE-D, or OE-ctrl. As a negative control, WT adult NSPC were infected with sh-Ctrl and OE-ctrl lentivirus. Consistent with our previous findings (), abrogation of H2-Kb resulted in an increase in EdU-positive proliferating cells (); however, this effect was mitigated by overexpression of H2-Kb but not H2-Db (). Collectively, these in vivo and in vitro data indicate that H2-Kb is sufficient to impair adult hippocampal neurogenesis and NSPC proliferation.

H2-Kb regulates NSPC proliferation by inhibiting Fgfr-mediated signaling

To gain mechanistic insight into how MHC I molecules regulate NSPC proliferation, we profiled gene expression in primary NSPCs derived from K−/−, D−/−, and WT mice using RNA-seq. Hierarchical clustering revealed high similarity between biological replicates within individual genotypes (average Pearson correlation coefficient; PCC >0.99). Interestingly, replicates from K−/− NSPCs were segregated from all other genotypes (). As expected, we found a larger number of differentially expressed genes (844 genes) between K−/− and WT NSPCs compared to D−/− and WT (118 genes) NSPCs (). Next, we focused on genes whose expression was significantly different between WT and K−/− NSPCs (). Among the most differentially up-regulated genes detected in K−/− NSPCs, we identified several growth factor and extracellular matrix protein encoding genes (); many of which are associated with increased NSPC proliferation [12]. Accordingly, we found “cell proliferation” among the most significantly enriched gene ontology (GO) terms ().

To elucidate pathways that might underlie increased proliferation observed in K−/− NSPCs, we made use of our RNA-seq dataset and performed pathway enrichment analysis (). Genes up-regulated in K−/− NSPCs comprised several growth factor receptor tyrosine kinase signaling pathways (). Apoptosis pathway-associated genes did not differ between groups, whereas p53 tumor suppressor pathway genes were down-regulated in K−/− NSPCs (). As multiple categories of growth factor signaling were enriched, we next surveyed growth factor receptor expression in WT NSPCs in our RNA-seq dataset and detected highest expression of Fgfr1 followed by Ntrk2, Fgfr3, Egfr, and Fgfr2 (). Next, we surveyed growth factor receptor expression in WT adult NSPCs following viral-mediated abrogation and overexpression of H2-Kb or H2-Db by qPCR (Figs and ). We observed a selective bidirectional change in Fgfr1 and Fgfr3 in WT NSPCs infected with sh-K and OE-K lentivirus, in which Fgfr1 and Fgfr3 expression increased following H2-Kb abrogation and decreased following H2-Kb overexpression (). Correspondingly, we examined whether downstream growth factor receptor tyrosine kinase signaling pathways were more highly activated following H2-Kb abrogation. We assessed Akt and Erk pathways in WT adult NSPCs infected with sh-K and grown under absent (0 ng/mL), low (5 ng/mL), or normal (20 ng/mL) FGF conditions. Western blot analysis showed that decreased H2-Kb expression enhanced phosphorylation of Erk (Thr202/Tyr204) but not Akt (Tyr450) (). Ribosomal protein S6, a downstream target of receptor tyrosine kinase signaling involved in cell proliferation, was also more highly phosphorylated (Ser235/236) following H2-Kb abrogation (). These data suggest that H2-Kb negatively regulates NSPC proliferation through inhibition of receptor tyrosine kinase signaling pathways downstream of Fgfr signaling.

Given that Fgfr1 showed highest growth factor receptor expression in WT NSPCs () and exhibited bidirectional gene expression changes following H2-Kb abrogation and overexpression (), we opted to investigate the functional role of Fgfr1 in mediating the effects of decreased H2-Kb expression on cell proliferation. We generated lentiviral constructs encoding shRNA sequences targeting Fgfr1 (sh-Fgfr1) and knockdown was confirmed by qPCR (). WT adult NSPC were infected with sh-K or sh-Ctrl lentivirus in combination with sh-Fgfr1 or sh-Ctrl and treated with EdU. Consistent with our previous findings (Figs ), decreased H2-Kb expression resulted in an increase in EdU-positive proliferating cells (); however, this effect was mitigated by abrogation of Fgfr1 (). Similar findings were observed in vitro following treatment with an FGFR pharmacological inhibitor (). Last, we examined whether mimicking the increase in Fgfr1 expression observed following H2-Kb abrogation () could likewise increase in NSPC proliferation. We generated lentiviral constructs encoding Fgfr1 (OE-Fgfr1) under the control of the Nestin promoter and overexpression was confirmed by qPCR (). Increased expression of Fgfr1 resulted in a significant increase in EdU-positive proliferating cells compared to control (). Altogether, these data indicate that H2-Kb molecules negatively regulate NSPC proliferation by inhibiting Fgfr1-mediated signaling.

Discussion

In this study, we identify classical MHC I molecule H2-Kb as a negative regulator of hippocampal neurogenesis. Using genetic knockout mouse models, viral-mediated RNAi and overexpression approaches, and primary NSPC cultures, we demonstrate that H2-Kb negatively regulates adult neurogenesis and NSPC proliferation. Subsequent transcriptomic analysis of WT and K−/− NSPCs, in combination with in vitro RNAi, overexpression, and pharmacological approaches, revealed that H2-Kb inhibits cell proliferation by dampening signaling pathways downstream of Fgfr1. Collectively, our findings attribute H2-Kb a previously unrecognized inhibitory role in NSPC function. As many CNS disorders with neurogenic dysfunction also coexhibit changes in MHC I expression [32-34], our findings provide a unique molecular target to promote the innate regenerative capacity of the CNS to combat such brain insults.

Previous studies investigating classical MHC I molecules in the CNS have utilized broad genetic manipulations, where β2-microglobulin and transporter associated with antigen processing 1 (Tap1), in which MHC I molecules cannot be trafficked to the cell membrane, were constitutively deleted in the whole body. These models targeted MHC I as a whole class of molecules, as they decreased global cell surface expression of most, if not all, murine MHC I proteins indiscriminately. Due to the available genetic models, there has been a general assumption that classical MHC I subtypes performed analogous functions in the brain. However, as MHC I molecules comprise of a highly polymorphic gene family with over 50 sequences described, it is critical to begin to elucidate specific roles and cell-type significance for individual MHC I molecules in the CNS. Recently, it was shown that reintroduction of neuronal H2-Db selectively could reverse synaptic deficits in KD−/− mice, suggesting that a single MHC I molecule was sufficient to rescue functional synapse elimination and refinement in the visual system [35]. Concordantly, we examined involvement of H2-Kb and H2-Db separately in single knockout models and using NSC-specific viral-mediated overexpression approaches. While we do not exclude a role for H2-Db in NSPC function, our data reveal a distinct role for H2-Kb in directing NSPC proliferation and hippocampal neurogenesis. Additionally, in this study, spatially and temporally controlled H2-Kb and H2-Db abrogation using RNAi in WT mice further allowed us to tease apart the general effects of systemic immune compromise in genetic knockout models from absence of H2-Kb and H2-Db selectively in the hippocampus. The functional difference observed between H2-Kb and H2-Db may stem from disparities in structure, spatiotemporal distribution, or binding partners, and future studies are required for detailed comparative characterization.

Our study also provides the first unbiased transcriptomic insight into pathways that may lie downstream of MHC I in the CNS. RNA-seq analysis revealed enrichment of several growth factor receptor signaling pathways in K−/− NSPCs, of which Fgfr1 exhibited bidirectional gene expression changes following H2-Kb abrogation and overexpression. Mechanistically, we further demonstrate that H2-Kb molecules negatively regulate NSPC proliferation by inhibiting Fgfr1-mediated signaling. To date, studies have shown that a number of soluble growth factors, such as insulin-like growth factor 1 (IGF1), vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), FGF2, and EGF regulate adult neurogenesis [12]. Interestingly, it has recently been demonstrated that restoring growth factor signaling by increasing FGF2 or EGF in the neurogenic niche or activating Fgfr in adult NSPCs is sufficient to enhance adult neurogenesis in rodents where aging or neurodegenerative disease has caused functional decline of stem cell function [36-38]. It is promising that despite pathological neurogenic decline, the remaining endogenous NSPCs are amenable to rejuvenation through activation of growth factor signaling. Further insights into precisely how interactions between H2-Kb and growth factor receptors affect their trafficking dynamics, internalization, expression, and signaling specifically on NSPCs will be required to better understand how H2-Kb can be therapeutically targeted under conditions of aging and neurodegenerative disease.

Under physiological conditions, neurogenesis has been implicated in spatial learning and memory, pattern separation, and affective behaviors [39]. Although tightly controlled, this process is highly vulnerable under pathological conditions: In mammalian models, NSPC loss of function occurs in aging and neurodegenerative disorders, while aberrant gain of NSPC proliferation can occur in epilepsy and schizophrenia [14,40]. Preventing NSPC dysfunction may be essential for restoring brain function under pathological conditions, and identification of specific molecules and mechanisms controlling neurogenesis will inform translational efforts. Our finding that H2-Kb uniquely regulates NSPC proliferation suggests that classical MHC I molecules exhibit polymorphic biological functions in the brain. This posits that certain individual MHC I variants may selectively modulate susceptibility for neurological disorders. Indeed, MHC I molecules have been implicated in several CNS and systemic diseases—many of which present with NSPC dysfunction—by human genome-wide association studies (GWAS). Single nucleotide polymorphisms on the MHC complex region on chromosome 6 have been linked with highly significant disease risk in schizophrenia and age-associated disorders [41-44]. In addition to a genetic association to disease, MHC I expression has directly been shown to be dynamic in certain pathophysiological states: MHCI molecules increase in rodent hippocampal neurons and neuromuscular junctions with age, interfering with synaptic homeostasis [32,34], and an up-regulation of neuronal H2-Kb, H2-Db, and MHC I receptor, PirB, is observed in stroke [33]. As animals lacking H2-Kb and H2-Db are protected from tissue damage and exhibit enhanced motor recover after stroke [33], it remains for future studies to now test whether targeting H2-Kb molecules in the aging hippocampus could prevent, or even reverse, age-related neurogenic decline.

Methods

Experimental model and subject details

All experiments were randomized and blinded by an independent researcher prior to pharmacological treatment or assessment of genetic mouse models. Researchers remained blinded throughout histological and biochemical assessments. Groups were unblinded at the end of each experiment upon statistical analysis. A key resource table can be found in the Supporting information (S1 Table).

Mouse models

All animal handling and use was approved by the Institutional Animal Care and Use Committee at the University of California San Francisco (AN178706-03B), in compliance with all applicable provisions of the Animal Welfare Act and Regulations (AWAR), the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals, and other federal regulations and policies relating to the use of animals in research and instruction. All mice were group housed under specific pathogen-free conditions under a 12-hour light–dark cycle with ad libitum access to food and water.

The following mouse lines were used: C57BL/6 (Taconic), H2-K and H2-D1 (KD−/−) double knockout mice (Taconic), H2-K1 (K−/−) single knockout mice (Taconic), and H2-D1 (D−/−) single knockout mice (Taconic), and C57BL/6J (The Jackson Laboratory). C57BL/6J mice were used for all stereotaxic injection experiments. All studies were conducted using male animals. The number of mice used to result in statistically significant differences was calculated using standard power calculations with α = 0.05 and a power of 0.8. We used an online tool (http://www.stat.uiowa.edu/~rlenth/Power/index.html) to calculate power and samples size based on experience with the respective tests, variability of the assays, and interindividual differences within groups.

Immunohistochemistry

Tissue processing and immunohistochemistry were performed on free-floating sections following standard published techniques [26]. Briefly, mice were anesthetized with a ketamine (100 mg/kg)-xylazine (10 mg/kg) cocktail (Patterson Veterinary, Henry Schein) and transcardially perfused with cold PBS. Brains were removed, fixed in phosphate-buffered 4% paraformaldehyde (pH 7.4), at 4°C for 48 hours followed by cryoprotection in 30% sucrose, and coronally sectioned at 40 μm with a cryomicrotome (Leica SM2010 R). Sections were washed 3 times in Tris-buffered saline with 0.1% Tween 20 (TBST) and incubated in 3% normal donkey serum (Thermo Fisher Scientific) for 1 hour. After overnight incubation in primary antibody (see S1 Table) at 4°C, staining was revealed using fluorescence conjugated secondary Alexa antibodies (1:500; see S1 Table). Antigen retrieval for BrdU labeling required incubation in 3M HCl at 37°C for 30 minutes before incubation with primary antibody; Nestin labeling required incubation in citrate buffer (Sigma-Aldrich Cat# C9999-100ML) at 95°C (3 times 5 minutes) prior to incubation with primary antibody. For EdU labeling, brain sections were incubated with freshly made EdU reaction mixture for 45 minutes at room temperature following the manufacturer’s instructions. Then, sections were washed, blocked, and incubated with primary antibodies following the regular immunostaining protocol. To estimate the total number of immunopositive cells per DG, confocal stacks of coronal sections of the DG (4 to 6 sections per mouse, 40 μm thick, 240 μm apart) were acquired on a Zeiss LSM 800. Immunopositive cells in the granule and subgranular cell layers were then counted and multiplied by 12 to estimate the total number in the entire DG.

Western blot analysis

Primary NSCs were lysed in prechilled RIPA lysis buffer (500 mM Tris (pH 7.4), 150 mM NaCl, 0.5% Na deoxycholate, 1% NP40, 0.1% SDS) supplemented with complete protease inhibitor cocktail (Sigma cat# 11697498001) and Halt phosphatase inhibitor cocktail (Thermo Fisher Scientific cat# 78420). Cell lysates were incubated for 15 minutes on ice and cleared using 10-minute 15,000 rpm centrifugation at 4C. Protein concentrations were measured using a BCA protein assay kit (Thermo Fisher Scientific cat# PI23225). Protein lysates were mixed with 4× NuPage LDS loading buffer (Invitrogen), heat denatured, loaded on a 4% to 12% SDS polyacrylamide gradient gel (BioRad cat # 3450124), and subsequently transferred onto a nitrocellulose membrane. The blots were blocked in 5% milk in TBST and incubated with primary antibody at 4°C for 16 hours. Horseradish peroxidase–conjugated secondary antibodies and an ECL kit (BioRad cat # 1705060 and 1705062) were used to detect protein signals. Multiple exposures were taken on a BioRad ChemiDoc. Images were exported (300 dpi) and quantified using the Gels tool in FIJI/ImageJ (Version 2.1.0). GAPDH, total Erk, and Akt bands were used for normalization.

RNA isolation and qRT-PCR

mRNA of NSCs was isolated by lysis with TRIzol Reagent (Thermo Fisher Scientific), separation with chloroform (0.2 mL per mL TRIzol), and precipitated with isopropyl alcohol. mRNA from DG tissue was isolated with the Rneasy Mini Kit (Qiagen). High Capacity cDNA Reverse Transcription Kit (Life Technologies) was used for reverse transcription of mRNA into cDNA, and qRT-PCR was carried out using Power SYBR Green PCR Master Mix (Life Technologies) in a CFX384 Real Time System (Bio-Rad). Primers were: H2-Kb forward 5′-CGGCGCTGATCACCAAACA-3′, H2-Kb reverse 5′-AGCGTCGCGTTCCCGTT-3′; H2-Db forward 5′ -GTAAAGCGTGAAGACAGCTGC- 3′, H2-Db reverse 5′-CTGAACCCAAGCTCACAGG-3′ (3′UTR); H2-Db forward-2 5′—3′; H2-Db reverse-2 5′—3′ (CDS); GAPDH forward 5′-GCATCCTGCACCACCAACTG-3′, GAPDH reverse 5′-ACGCCACAGCTTTCCAGAGG-3′. Fgfr1 forward 5′-CTTGCCGTATGTCCAGATCC-3′; Fgfr1 reverse 5′-TCCGTAGATGAAGCACCTCC-3′; Fgfr2 forward 5′-TGCATGGTTGACAGTTCTGC-3′; Fgfr2 reverse 5′-GCAGGCGATTAAGAAGACCC-3′; Fgfr3 forward 5′-GAAGCACGTGGAAGTGAACG-3′; Fgfr3 reverse 5′-TCCTTGTCGGTGGTGTTAGC-3′; Egfr forward 5′-GGACTGTGTCTCCTGCCAGAAT-3′; Egfr reverse 5′-GGCAGACATCCTGGATGGCACT-3′; Ntrk2 forward 5′-TTACGTGGGGCTGAGAAACC-3′; Ntrk2 reverse 5′-TCCTGGACAAACTCGTCAGC-3′. All primer pairs display a single peak using melting curve analysis.

BrdU/EdU administration and quantification

For short-term proliferation studies, mice were intraperitoneally injected with Brdu (Brdu-short) or EdU (50 mg/kg body weight, Thermo Fisher Scientific) 5 days before euthanasia. For study of newborn neuron survival, mice were injected with BrdU (BrdU-long) for 5 consecutive days, and animals were euthanized 28 days after administration. Stereotaxically injected animals received their first injection after a minimum of 2 weeks to 1 month of recovery from surgery. EdU labeling was revealed using the Click-it kit (Thermo Fisher Scientific) following the manufacturer’s instruction. To estimate the total number of BrdU-positive cells in the brain, we performed fluorescence staining for BrdU on 3 to 6 hemibrain sections per mouse (40 μm thick, 240 μm apart). The number of EdU/BrdU-positive cells in the granule cell and subgranular cell layer of the DG was counted and multiplied by 12 to estimate the total number of EdU/BrdU-positive cells in the entire DG. To quantify neuronal fate and maturation of dividing cells, BrdU-positive cells across 4 to 6 sections per mouse were analyzed by confocal microscopy for coexpression with NeuN. For stereotaxially injected animal, 3 to 4 brain sections without damage, surrounding the injection site were analyzed, and cell numbers were computed as the average number of cells/section.

Stereotaxic injections

Animals were placed in a stereotaxic frame and anesthetized with 2% isoflurane (Patterson Veterinary) (2 L per min oxygen flow rate) delivered through an anesthesia nose cone. Fur around the incision area was trimmed, and ophthalmic eye ointment was applied to the cornea to prevent desiccation during surgery. Viral solutions were injected bilaterally into the dorsal hippocampi using the following coordinates: (from bregma) anterior = −2 mm, lateral = 1.5 mm and (from skull surface) height = −2.1 mm. A 2-μL volume of viral solution was injected stereotaxically over 10 minutes (injection speed: 0.20 μL per min) using a 5-μL 26s-gauge Hamilton syringe. To limit reflux along the injection track, the needle was maintained in situ for 8 minutes, slowly pulled out halfway, and kept in position for an additional 2 minutes. The skin was closed using silk suture. Each mouse was injected subcutaneously with enrofloxacin (Bayer) antibiotic and buprenorphine (Butler Schein) as directed for pain, single housed, and monitored during recovery. After a minimum of 2 weeks of recovery, animals were injected with BrdU for 5 consecutive days and euthanized 28 days following the final injection. During the last 5 days prior to euthanasia, all animals were intraperitoneally injected with EdU.

Isolation of primary neural stem cells from the postnatal and adult mouse hippocampus

Postnatal and adult primary NSC isolation and culture were preformed following previously published techniques [28]. Hippocampi were dissected from postnatal day 1 (P1) WT C57/BL6 control, KD−/−, K−/−, or D−/− mice, or adult (2 months) WT C57/BL6 mice and pooled by genotype for NSPC isolation without distinguishing genders. After removing superficial blood vessels, hippocampi were mechanically dissociated by fine mincing and enzymatically digested for 30 minutes at 37°C in DMEM media containing 2.5 U/ml Papain (Worthington Biochemicals), 1 U/ml Dispase II (Boeringher Mannheim), and 250 U/ml Dnase I (Worthington Biochemicals). NSCs were purified using a 65% Percoll gradient and cultured (Neural Basal A medium supplemented with 2% B27 without Vitamin A, 1% Glutamax, 1% Penicillin Streptomycin, 10 ng/ml EGF, 10 ng/ml bFGF) as a monolayer on poly-D-lysine and laminin-coated plates at a density of 105 cells/cm2.

NSC proliferation assay

WT or knockout NSPCs were seeded in 500 μL growth medium (Neural Basal A medium supplemented with 2% B27 without Vitamin A, 1% Glutamax, 1% Penicillin Streptomycin, 10 ng/ml EGF, 10 ng/ml bFGF) at a density of 10,000 cells/well on PDL/laminin-coated glass coverslips in a 24-well tissue culture plate. Twenty-four hours later, cells were treated with 20 μM BrdU or EdU for 6 hours prior to fixing with 4% PFA. Acute knockdown of H2-Kb, H2-Db, or both was induced by treating plated WT NSCs with shRNA-encoding lentiviruses (6.5 × 106 to 7.5 × 106 viral particles per mL media) for 3 days prior to BrdU or EdU treatment as described. For experiments requiring a combination of 2 different viruses, only half the concentration of virus was added to the media for each virus. Cells were washed 3 times with PBS after fixation, blocked in 3% donkey serum, and incubated in primary antibody at 4°C for 16 hours. After 3 washes with PBS, BrdU staining was revealed with fluorescence-conjugated secondary Alexa antibodies (1:500; see S1 Table). EdU incorporation was revealed using a Click-iT EdU Alexa Fluor Imaging Kit (Thermo Fisher Scientific), and nuclei were counterstained with Hoechst 33342 (1:10,000; Thermo Fisher Scientific). BrdU- or EdU-positive cells were counted per field of view at 3 to 4 randomly determined locations per coverslip. In vitro experiments were conducted in triplicates for each condition (unless stated otherwise) and repeated to ensure reproducibility. For inhibitor experiments, NSPCs were pretreated for 1 hour with an Fgfr inhibitor (PD 161570, 0.1uM) prior to the 6-hour EdU pulse.

Cell cycle analysis by cumulative EdU labeling

WT and K−/− NSCs cultured in vitro in growth media were treated with 20 μM EdU at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 hours prior to fixation. Cells that incorporated EdU were labeled using the Click-iT Plus EdU Alexa Fluor Flow Cytometry Kit (Thermo Fisher Scientific) as per manufacturer’s instructions, and percentage of EdU+ cells was determined by flow cytometry. The labeling index (LI; percent of total cells positive for EdU) was plotted over time, increasing linearly until a plateau (which corresponds with the GF, or maximum percentage of cells actively proliferating) was reached. The data can be fitted with 2 regression lines (as described in Nowakowski and colleagues [45]): one line that describes the initial linear increase, and another that describes the horizontal line corresponding to the GF. The time (in the x axis) where the 2 regression lines intersect is equal to Tc − Ts, where Tc is the cell cycle length and Ts is the S phase length. The intersect of the first regression line and the y axis is defined as the initial labeling index (Li0) and is equal to GF × Ts/Tc. Using these equations and the regression lines, Tc and Ts were calculated for WT and K−/− NSCs. Each time point for both genotypes were conducted in duplicates.

Viral plasmids and viruses

We generated lentiviruses encoding shRNAs targeting endogenous H2-Kb (sh-K), H2-Db (sh-D), or both (sh-KD) using a lentiviral shRNA expression system (pGreenPuro shRNA, System Biosciences) according to the manufacturer’s instructions. The targeted sequences were cloned into the pGreenPuro vector (H2-Kb, 5′-GAATGTAACCTTGATTGTTAT-3′; H2-Db, 5′-ACCACACTCGATGCGGTATTTC-3′; H2-Kb H2-Db, 5′-ACCCTCAGTTCTCTTTAGTCAA-3′), Fgfr1 SH1 (5′-GTGACCGAGGATAACGTAATG-3′), Fgfr1 SH2 (5′-CTGGCTGGAGTCTCCGAATAT-3′), Fgfr1 SH3 (5′-TGAAGACTGCTGGAGTTAATA-3′), Fgfr1 SH4 (5′-CGCTCTACCTGGAGATCATTA-3′). After knockdown validation, Fgfr1 SH2 was used for further in vitro experiments. Plasmid quality was tested with western blot analysis and Sanger sequencing. For the lentiviral H2-K-1, H2-D-1, and Fgfr1 overexpression constructs, the whole CDS and part of the UTRs were amplified from Hippocampal cDNA and cloned into the pENTR-D-TOPO vector. From there, the CDS was further PCR amplified, and restriction enzyme sites were incorporated into the forward and reverse primers. H2-K1 and H2-D1 CDS were cloned into the Nestin promoter-based lentiviral plasmid [21] using traditional restriction enzyme-based cloning strategy with NheI and BamHI. Fgfr1 was cloned using NotI and SalI. A Nestin-GFP construct based on the same plasmid backbone was used as a control. The final plasmid sequences were verified using Sanger sequencing. LV vectors were generated at the UCSF Viracore, with viral titers between 1.2 × 109 to 1.5 × 109 viral particles per mL. Viral solutions were diluted to 1.0 × 108 viral particles/ml prior to injection. Lentiviruses were stereotaxically injected into the right DG, and a control virus encoding a scrambled shRNA sequence (sh-control, 5′-GGACGAACCTGCTGAGATAT-3′) or Nestin-GFP into the left contralateral DG.

Bioinformatic analysis of single cell RNA-sequencing data from Shin and colleagues [27]

Pseudotime assignment and read counts (CPM) for all cells were obtained from Shin and colleagues [27]. Read counts were log2 transformed (log2(CPM+1)) and scaled between 0 and 1 by dividing the normalized read count for each gene in each cell by the maximum expression value across all cells for the respective gene. Cells were then ordered according to their pseudotime estimate from early to late. Subsequently, a local polynomial regression line was fit alone the trajectory, and the 95% confidence interval was calculated using the ggplot2 R package. Time points T1 and T2 were determined by the time of increasing Tbr2 expression (rightmost stationary point of the Tbr2 regression line calculated in R). G1 and G2 cell cycle score were calculated as the summed expression of G1 and G2 markers, as published in Tirosh and colleagues [29], divided by the median score across cells.

NSC RNA-sequencing library construction

After RNA isolation, RNA-seq libraries were constructed using the Smart-Seq2 protocol from Trombetta and colleagues [46], with modifications. Briefly, 1 ng high-quality RNA was reverse transcribed using SuperScript II (Life Technologies, 18064–014) with a poly-dT anchored oligonucleotide primer and a template switching oligonucleotide primer that generated homotypic PCR primer binding sites. The cDNA underwent 10 rounds of PCR amplification using KAPA HiFi Hotstart (Kapa Biosystems, KK2601), followed by Ampure bead (Agencourt) cleanup. The quality of the amplified cDNA was tested using qPCR for GAPDH and nucleic acid quantitation. High-quality amplified cDNA (1 ng) was fragmented with the Tn5 transposase from the Illumina Nextera kit (FC-131-1096) to a median size of approximately 500 bp. The fragmented library was amplified with indexed Nextera adapters (FC-131-1002) using 12 rounds of PCR. Final libraries were purified with Ampure beads and quantified using a qPCR Library Quantification Kit (Kapa Biosystems, KK4824). Libraries were pooled for sequencing on an Illumina HiSeq 2500.

Bioinformatic analysis of NSC RNA-sequencing data

Quality trimming and adapter removal of raw FASTQ files were carried out with cutadapt. Only reads longer than 20 base pairs were kept for downstream analysis. Subsequently, trimmed reads were mapped to the mouse genome (Grchm38) using HISAT2 [47]. Transcripts given by the GENCODEv25 reference (https://www.gencodegenes.org/mouse/) were quantified with featureCounts [48], considering only uniquely aligned reads. Differential expression tests were calculated using Deseq2 [49], and transcripts with an adjusted p-value < 0.05 were considered differentially expressed. ConsensusPathDB [50] was used for calculation of pathway enrichments. Raw NSC RNA-seq data have been uploaded to Array Express: E-MTAB-5827.

Statistical analysis

Statistical tests were performed with GraphPad Prism 6 and 8. All data are represented as mean +/− SEM. Differences between treatment conditions were established using an unpaired Student t test (for 2 conditions). For experiments with > 2 groups, a one-way ANOVA with a Dunnett’s multiple comparison test for comparison to a single control group or a Tukey’s multiple comparison test for individual comparison between all groups was used. A two-way ANOVA with Sidak’s multiple comparison test was used for western blot analysis with both H2-K1 and Fgf manipulations. P < 0.05 was considered statistically significant. Additional statistic details are indicated in the respective figure legends. The numerical data used in all figures are included in in the Supporting information (S1 Data).

Single-cell transcriptomic characterization of Tbr2 and GFAP expression during neurogenesis.

The neurogenic lineage was divided into an early time point (T1) where NSCs express GFAP, and a later time point (T2) where differentiating intermediate neural progenitors begin to express Tbr2. (A) Waterfall plot illustrates the relative expression of Tbr2 and GFAP along a trajectory of adult neurogenesis, as described in Fig 1A. The cutoff point between time points T1 and T2 was determined by the time of increasing Tbr2 expression (last stationary point of the Tbr2 regression line). Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). GFAP, glial fibrillary acidic protein; NSC, neural stem cell; Tbr2, T-box brain protein 2.

Fig 1

H2-Kb, and not H2-Db, negatively regulates adult hippocampal neurogenesis and NSPC proliferation.

Relative expression of H2-K1 (H2-Kb), H2-D1 (H2-Db), and Mki67 (Ki67) along a bioinformatically assigned trajectory of adult neurogenesis. Single adult hippocampal NSCs were ordered according to pseudotime (x-axis) estimates as given in [27]. Relative gene expression (y-axis, log2(CPM+1)/max(log2(CPM+1))) was fitted with local polynomial regression fitting (bold lines) with 95% confidence interval (light colored area). The cutoff point between time points T1 and T2 was determined by the time of increasing Tbr2 expression (last stationary point of the Tbr2 regression line; see S1 Fig) (A). Number of cells positive for H2-K1, H2-D1, Ki67, and Gapdh expression (y-axis) between T1 and T2 (B). Neurogenesis was characterized in 3-month-old WT, H2-Kb knockout (K−/−), and H2-Db knockout (D−/−) mice (C). Representative field (D) and quantifications (E) of Nestin+ NSCs, EdU+ short-term proliferating cells, Dcx+ neuroblasts, and adult-born neurons coexpressing BrdU-long and NeuN in the DG. n = 3–5 mice/group (3–6 hippocampal sections/mouse); scale bars: 50 μm (D). Adult (3 months) WT mice were stereotaxically injected with lentivirus encoding an H1 promoter-driven shRNA targeting H2-Kb (sh-K) or H2-Db (sh-D) in one DG and shRNA targeting luciferase as a control (sh-Ctrl) in the contralateral DG (F). (G) Quantification of EdU+ proliferating cells (left panel), Dcx+ neuroblasts (middle panel), and BrdU-long/NeuN double-positive mature neurons (right panel) in sh-K- and sh-D-injected DG compared to sh-control-injected DG (F). n = 4–8 DG/group (3–4 sections/DG). (H) Primary hippocampal WT, K−/−, and D−/− NSPCs cultured under self-renewal conditions were treated with EdU for 6 hours. Representative field shown and mean percentage of EdU+ dividing cells were quantified. n = 3 replicates/group; scale bars: 50 μm. (I) WT postnatal (left panel) and adult (right panel) NSPCs infected with lentiviruses encoding sh-K, sh-D, and sh-control were cultured under self-renewal conditions and treated with EdU for 6 hours. Percentage of EdU+ postnatal and adult cells are shown. n = 3 replicates/group. Data are represented as mean ± SEM; Fisher’s exact test (B); ANOVA with Dunnett’s post hoc test (E, G, H, I); *p < 0.05, **p < 0.01, ***p < 0.001. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). BrdU, 5-bromo-2′-deoxyuridine; Dcx, Doublecortin; DG, dentate gyrus; EdU, 5-ethynyl-2′-deoxyuridine; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Gfap, glial fibrillary acidic protein; NeuN, neuronal nuclei; n.s., not significant; NSC, neural stem cell; NSPC, neural stem and progenitor cell; shRNA, short hairpin RNA; Tbr2, T-box brain protein 2; WT, wild-type.

(PDF)

Click here for additional data file.

Characterization and validation of MHC I knockout, knockdown, and overexpression.

Quantitative RT-PCR of H2-Kb (left panel) and H2-Db (right panel) mRNA from primary NSPCs isolated from WT, K−/−, and D−/− knockout mice (A). n = 3 replicates/group. Quantitative RT-PCR of H2-Kb (left panel) and H2-Db (right panel) mRNA from primary NSPCs isolated from WT and KD−/− double knockout mice (B). n = 3 replicates/group. Quantitative RT-PCR of H2-Kb (left panel) and H2-Db (right panel) mRNA from primary WT NSPCs infected with lentiviruses encoding shRNA targeting H2-Kb (sh-K) or H2-Db (sh-D) or luciferase control (sh-Ctrl) 72 hours after infection (C). n = 4 replicates/group. Quantitative RT-PCR of H2-Kb (left panel) and H2-Db (right panel) mRNA from primary WT NSPCs infected with lentiviruses encoding shRNA concomitantly targeting both H2-Kb and H2-Db (sh-KD) or luciferase as a control (sh-Ctrl) (D). n = 4 replicates per group. Quantitative RT-PCR of H2-Kb (left panel) and H2-Db (right panel) mRNA from primary WT NSPCs infected with lentiviruses overexpressing H2-Kb (OE-K), H2-Db (OE-D), or GFP as a control (OE-ctrl) under the Nestin promoter (C). n = 4 replicates/group. All data represented as mean ± SEM; one-way ANOVA with Dunnett’s post hoc test (A, C, E) and Student t test (B,D); ****p < 0.0001. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). MHC I, major histocompatibility complex class I; NSPC, neural stem and progenitor cell; RT-PCR, reverse transcription polymerase chain reaction; shRNA, short hairpin RNA; WT, wild-type.

(PDF)

Click here for additional data file.

Characterization of hippocampal composition in MHC I knockout mouse models.

(A) Quantification of Iba1 (a microglial marker) and the percent of microglia coexpressing the activation marker CD68 in the DG of 2–3 months old WT, K−/−, and D−/− knockout mice. n = 4 animals/group (3–6 sections/animal). (B, C) Quantification of GFAP-positive astrocytes (B) or overall DG size using the neuronal marker NeuN (C). n = 4–5 animals/group (3–4 sections/animal). All data represented as mean ± SEM. ANOVA with Dunnett’s post hoc test. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). CD68, cluster of differentiation 68; DG, dentate gyrus; GFAP, glial fibrillary acidic protein; Iba1, ionized calcium-binding adapter molecule 1; MHC I, major histocompatibility complex class I; NeuN, neuronal nuclei; n.s., not significant; WT, wild-type.

(PDF)

Click here for additional data file.

Neurogenesis is increased in H2-Kb/H2-Db double knockout mice, and proliferation is increased in primary NSPCs.

(A) Neurogenesis was characterized in 2-month-old WT and H2-Kb/H2-Db double-knockout (KD−/−) mice. Quantifications of Nestin+ NSCs, BrdU+ short-term proliferating cells, Dcx+ neuroblasts, and adult-born neurons coexpressing BrdU-long and NeuN in the DG. n = 3–5 animals/group (3–6 hippocampal sections/animal). (B) Quantification of Iba+ microglia and the percent of Iba+ microglia expressing CD68 in the DG of adult (2 months) WT or KD−/− mice. N = 4 animals/group (3–6 hippocampal sections/animal). (C) Primary NSPCs isolated from the hippocampi of WT, KD−/− mice were cultured under self-renewal conditions and treated with EdU for 6 hours. Percentage of EdU+ cells are shown (C). n = 3 replicates/group. (D) WT postnatal (left panel) and adult (right panel) NSPCs infected with lentiviruses encoding sHRNA concomitantly targeting H2-Kb and H2-Db (sh-KD) or targeting luciferase as a control (sh-Ctrl) were cultured under self-renewal conditions and treated with EdU for 6 hours. Percentage of EdU+ cells are shown (D). n = 3 replicates/group. All data represented as mean ± SEM. Student t test; *p < 0.05. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). BrdU, 5-bromo-2′-deoxyuridine; CD68, cluster of differentiation 68; Dcx, Doublecortin; DG, dentate gyrus; EdU, 5-ethynyl-2′-deoxyuridine; Iba1, ionized calcium-binding adapter molecule 1; NeuN, neuronal nuclei; n.s., not significant; NSC, neural stem cell; NSPC, neural stem and progenitor cell; shRNA, short hairpin RNA; WT, wild-type.

(PDF)

Click here for additional data file.

No apparent alteration in neuronal differentiation potential in NSPCs lacking H2-Kb or H2-Db.

WT, K−/−, and D−/− NSPCs were cultured under growth factor-free conditions and allowed to differentiate for 6 days. Representative field (A) and quantification (B) of Map2+ neurons and GFAP+ astrocytes. Data represented as mean percentages ± SEM; n = 3 replicates per group; ANOVA, with Dunnett’s post hoc test (B). (C) WT adult NSPCs were infected with shRNA lentiviruses against H2-Kb (sh-K), H2-Db (sh-D), or luciferase (sh-Ctrl). Seventy-two hours after infection, NSPCs were transitioned to growth factor-free culturing conditions and allowed to differentiate for 6 days. Quantification (C) of Map2+ neurons (left panel) and GFAP+ astrocytes (right panel). All data represented as mean percentages ± SEM; n = 8 replicates/group. ANOVA with Dunnett’s post hoc test. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). GFAP+, glial fibrillary acidic protein-positive; Map2+, microtubule-associated protein 2-positive; n.s., not significant; NSPC, neural stem and progenitor cell; shRNA, short hairpin RNA; WT, wild-type.

(PDF)

Click here for additional data file.

Loss of H2-Kb in NSPCs alters cell cycle dynamics.

(A, B) A publicly available dataset of single adult hippocampal NSCs [27] was sorted by expression of G1 (x-axis) and G2 (y-axis) cell cycle scores as described in Tirosh and colleagues [29]. Cells positive for H2-K1 expression are indicated in red (A). (B) The percentage of cycling cells was found to be lower in H2-K1-positive cells (5.6%, 1 cycling cell, 17 noncycling cells) versus H2-K1-negative cells (24.4%, 20 cycling cells, 62 noncycling cells); odds ratio: 0.18. (C) Primary hippocampal WT and K−/− NSPCs cultured under self-renewal conditions were treated with EdU at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 hours prior to fixation, and percentage of EdU+ cells was determined by flow cytometry. Percent of cells incorporating EdU reached a plateau at 13.47 hours for WT NSPCs and 13.24 hours for K−/− NSPCs (Tc − Ts) when the cycling population (GF) entered the S phase. Linear regression for increasing phase of WT NSPCs: y = 0.6133 × + 7.996; R2 = 0.829 and K−/− NSPCs: y = 1.165 × + 7.406; R2 = 0.889. Values for cell cycle parameters calculated from cumulative labeling are shown in the right panel. (C). n = 3 replicates per group for in vitro experiments. Data represented as mean ± SEM; two-way repeated measures ANOVA with Sidak’s post hoc test (K); *p < 0.05, **p < 0.01, ***p < 0.001. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). EdU, 5-ethynyl-2′-deoxyuridine; GF, growth fraction; NSC, neural stem cell; NSPC, neural stem and progenitor cell; Tc, length of cell cycle; Ts, length of S phase; WT, wild-type.

(PDF)

Click here for additional data file.

Related to Fig 3. Loss of H2-Kb induces gene expression changes in NSPCs.

RNA-seq analysis of primary hippocampal WT, K−/−, and D−/− NSPCs cultured under self-renewal conditions. (A) Venn diagram illustrating the number of genes differentially expressed (DESeq2 adj. p < 0.05) between WT, K−/−, and D−/− NSPCs. (B) Scatterplot of the average gene expression in WT (x-axis) and K−/− (y-axis) NSPCs. Differentially expressed genes (DESeq2 adj. p < 0.05, 432 down- and 408 up-regulated) are indicated in red. Genes shown in heatmap (Fig 3B) are colored in blue. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). NSPC, neural stem and progenitor cell; RNA-seq, RNA-sequencing; WT, wild-type.

Fig 3

H2-Kb negatively regulates NSPC proliferation by inhibiting Fgfr signaling.

RNA-seq analysis of primary hippocampal WT, K−/−, and D−/− NSPCs cultured under self-renewal conditions. Pairwise distances (Euclidean distance) between RNA-seq libraries prepared from WT, K−/−, and D−/− primary hippocampal NSPCs. Dendrogram was calculated by unsupervised hierarchical clustering (average linkage). (n = 3 replicates/group [denoted R1–R3]) (A). (B) Unsupervised hierarchical clustering of growth factor signaling-related genes identified to be differentially expressed between WT and K−/− hippocampal NSPCs using RNA-seq analysis (z-score normalized, rows). (C) Cellular and signaling pathways identified by pathway enrichment analysis (ConsensusPathDB) of genes differentially expressed between WT and K−/− NSPCs are subdivided in gray. Outer ring illustrates expression of altered genes (log2 fold change between K−/− vs WT) within each pathway. Inner ring illustrates significance (−log10 adj. p-value) and overall expression levels of genes within each pathway (z-score). (D) Expression (FPKM) of growth factor receptors and H2-K1 and H2-D1 was evaluated in WT NSPCs using RNA-seq. n = 3 replicates/group for all RNA-seq analysis. (E) WT adult NSPCs were infected with either sh-K and sh-control (sh-Ctrl) or Nestin-driven K overexpression (OE-K) and GFP control (OE-Ctrl) lentiviruses. Fgfr1/Fgfr3 expression were measured using quantitative RT-PCR 72 hours after infection. n = 4 replicates/group. (F) Representative western blot (left panel) and quantifications (right panels) of activated Akt, Erk, and ribosomal protein S6 in adult WT NSPCs infected with lentiviruses encoding sh-K or sh-control (sh-Ctrl). NSPCs were grown in the absence of (0 ng/mL), low (5 ng/mL), or regular (20 ng/mL) FGF level for 2 hours. n = 2–3 replicates/time point/group; data represented as mean ± SD. (G) Representative images (left panel) and quantification (right panel) of adult NSPCs infected with sh-K or sh-Ctrl in combination with lentiviruses expressing shRNAs against Fgfr1 (sh-Fgfr1) or control (sh-Ctrl). NSPCs were grown under self-renewal conditions and treated with EdU for 6 hours to test for proliferation. Percentage of EdU+ cells are shown. n = 5 replicates/group. (H) Representative images (left panel) and quantification (right panel) of WT adult NSPCs infected with Nestin-Fgfr1 overexpression (OE-Fgfr1) or GFP control (OE-Ctrl) lentiviruses. NSPCs and cultured under self-renewal conditions treated with EdU for 6 hours to test for proliferation. Percentage of EdU+ cells are shown. n = 5 replicates/group. Data represented as mean ± SEM. One-way ANOVA with Dunnett’s multiple comparisons test (E, G), two-way ANOVA with Sidak’s multiple comparisons test (F), and Student t test (H). *p < 0.05, **p < 0.01, ****p < 0.0001. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). EdU, 5-ethynyl-2′-deoxyuridine; EGFR, epidermal growth factor receptor; FGF, fibroblast growth factor; Fgfr, fibroblast growth factor receptor; Fgfr1, fibroblast growth factor receptor 1; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein; NGF, nerve growth factor; n.s., not significant; NSPC, neural stem and progenitor cell; PDGF, platelet-derived growth factor; RNA-seq, RNA-sequencing; RT-PCR, reverse transcription polymerase chain reaction; shRNA, short hairpin RNA; WT, wild-type.

(PDF)

Click here for additional data file.

Related to Fig 3. Characterization of growth factor receptor expression in H2-Kb-deficient NSPCs.

WT adult NSPCs were infected with either sh-K, sh-D, and sh-control (sh-Ctrl) or Nestin-driven H2-Kb (OE-K), H2-Db (OE-D), and GFP control (OE-Ctrl) overexpression lentiviruses. NSPCs were grown under self-renewal conditions, and Fgfr2 (A), Ntrk2 (B), and Egfr (C) expression was measured using quantitative RT-PCR 72 hours after infection. n = 4 replicates/group. All data represented as mean ± SEM; one-way ANOVA with Dunnett’s multiple comparisons test; *p < 0.05; ***p < 0.001. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). Egfr, epidermal growth factor receptor; Fgfr2, fibroblast growth factor receptor 2; GFP, green fluorescent protein; n.s., not significant; NSPC, neural stem and progenitor cell; Ntrk2, neurotrophic tyrosine kinase receptor type 2; RT-PCR, reverse transcription polymerase chain reaction; WT, wild-type.

(PDF)

Click here for additional data file.

Characterization and validation of Fgfr1 knockdown and overexpression lentiviral tools.

(A) WT adult NSPCs were infected with 4 different shRNAs targeting Fgfr1 (sh-Fgfr1) or sh-control (sh-Ctrl) lentiviruses. NSPCs were grown under self-renewal conditions, and Fgfr1 expression was measured using quantitative RT-PCR 72 hours after infection. sh-Fgfr1(2) was selected for additional experiments. n = 4–5 replicates/group. (B) WT adult NSPCs were infected with a Nestin-driven Fgfr1 (OE-Fgfr1) or GFP control (OE-Ctrl) overexpression lentiviruses. NSPCs were grown under self-renewal conditions, and Fgfr1 expression was measured using quantitative RT-PCR 72 hours after infection. All data represented as mean ± SEM; one-way ANOVA with Dunnett’s multiple comparisons test (A) and Student t test (B); **p < 0.01; ****p < 0.0001. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). Fgfr1, fibroblast growth factor receptor 1; GFP, green fluorescent protein; NSPC, neural stem and progenitor cell; RT-PCR, reverse transcription polymerase chain reaction; shRNA, short hairpin RNA; WT, wild-type.

(PDF)

Click here for additional data file.

Inhibition of Fgfr signaling restores proliferation in H2-Kb-deficient NSPCs.

WT postnatal (D) and adult (E) NSPCs were infected with lentiviruses encoding sh-K and sh-control (sh-Ctrl), cultured under self-renewal conditions and exposed to Fgfr inhibitor PD 161570 (PD, 0.1 uM) or phosphate-buffered saline control for 1 hour and subsequently treated with EdU for 6 hours to test for proliferation (D, E). Data represented as mean percentage of EdU+ cells ± SEM. n = 3 replicates/group. Student t test; *p < 0.05 and **p < 0.01. Data used to generate this figure can be found in the Supporting information Excel spreadsheet (S1 Data). EdU, 5-ethynyl-2′-deoxyuridine; Fgfr, fibroblast growth factor receptor; n.s., not significant; NSPC, neural stem and progenitor cell; WT, wild-type.

(PDF)

Click here for additional data file.

Numerical data used to generate plots in all figures.

This Excel file contains multiple sheets, each of which contains the data that were used to generate plots in Figs 1–3 and S1–S10 (separated into different sheets for each figure panel).

(XLSX)

Click here for additional data file.

Uncropped western blots data related to Fig 3F.

(PDF)

Click here for additional data file.

List of reagents and tools used in this study.

(PDF)

Click here for additional data file.

17 Aug 2020

Dear Dr Villeda,

Thank you for submitting your manuscript entitled "MHC CLASS I H2-KbNEGATIVELY REGULATES NEURAL PROGENITOR CELL PROLIFERATION BY INHIBITING FGFR SIGNALING" for consideration as a Short Report by PLOS Biology.

Your manuscript has now been evaluated by the PLOS Biology editorial staff, as well as by an Academic Editor with relevant expertise, and I am writing to let you know that we would like to send your submission out for external peer review. The Academic Editor thinks, however, that it would be good if your move Fig. S4 to the main figures.

In addition, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Aug 19 2020 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pbiology

During resubmission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit http://journals.plos.org/plosbiology/s/preprints for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF when you re-submit.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Given the disruptions resulting from the ongoing COVID-19 pandemic, please expect delays in the editorial process. We apologise in advance for any inconvenience caused and will do our best to minimize impact as far as possible.

Feel free to email us at plosbiology@plos.org if you have any queries relating to your submission.

Kind regards,

Gabriel Gasque, Ph.D.,

Senior Editor

PLOS Biology

17 Sep 2020

Dear Dr Villeda,

Thank you very much for submitting your manuscript "MHC CLASS I H2-KbNEGATIVELY REGULATES NEURAL PROGENITOR CELL PROLIFERATION BY INHIBITING FGFR SIGNALING" for consideration as a Short Report at PLOS Biology. Your manuscript has been evaluated by the PLOS Biology editors, by an Academic Editor with relevant expertise, and by three independent reviewers.

In light of the reviews (below), we will not be able to accept the current version of the manuscript, but we would welcome re-submission of a much-revised version that takes into account the reviewers' comments. We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent for further evaluation by the reviewers.

We expect to receive your revised manuscript within 3 months.

Please email us (plosbiology@plos.org) if you have any questions or concerns, or would like to request an extension. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may end consideration of the manuscript at PLOS Biology.

**IMPORTANT - SUBMITTING YOUR REVISION**

Your revisions should address the specific points made by each reviewer. As you will see, all three reviewers agree that the study has potential for PLOS Biology. However, they also suggest a number of additional experiments and controls aimed at strengthening your core conclusion that H2-Kb negatively regulates NSPC proliferation and adult hippocampal neurogenesis. Additionally, there were concerns raised that the suggestion of FGFR signaling mechanism would also need to be bolstered with additional experimental support. Having discussed these comments with the Academic Editor, we think they all should be thoroughly addressed. However, we appreciate that to complement the genetic mutant model, and to circumvent potential developmental effects of a constitutive knockout, you have already used an in vivo viral-mediated RNAi approach. Therefore, we do not think this point is critical.

Please submit the following files along with your revised manuscript:

1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript.

*NOTE: In your point by point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point.

You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Related" file type.

*Re-submission Checklist*

When you are ready to resubmit your revised manuscript, please refer to this re-submission checklist: https://plos.io/Biology_Checklist

To submit a revised version of your manuscript, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' where you will find your submission record.

Please make sure to read the following important policies and guidelines while preparing your revision:

*Published Peer Review*

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*PLOS Data Policy*

Please note that as a condition of publication PLOS' data policy (http://journals.plos.org/plosbiology/s/data-availability) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5

*Blot and Gel Data Policy*

We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Gabriel Gasque, Ph.D.,

Senior Editor,

ggasque@plos.org,

PLOS Biology

*****************************************************

REVIEWS:

Reviewer's Responses to Questions

Reviewer #1: In their work Li et al. investigate the MHC molecule H2K1 as a regulator of proliferation during hippocampal neurogenesis. Using a mix of mouse genetics, in vitro analyses, expression analyses and biochemistry they provide evidence that H2K1 acts as a negative regulator of DG neurogenesis, acting not directly on the stem cells, but at later stages. They also claim the this action is mediated by the FGFR pathway.

The paper is well written. The mouse genetics approach is well designed and the analyses of these animals are convincing. The use of RNAi represents a good support for the mouse mutation analyses. Overall this is an interesting paper that has potential for publication in PLOSBio. However, there are some issues, in particular in the last FGFR-related part of the manuscript, that dampen my enthusiasm and that should be addressed.

First, as said, the loss of function studies in Fig. 1 are well performed and demonstrate that H2K1 is necessary to dampen DG neurogenesis. It would be interesting, and nicely complementary, to see what happens if the molecule is overexpressed and/or maintained at later stages in stem cells, in a gain of function approach. Is it sufficient to decrease proliferation? Is downregulation of H2K1 necessary? As the authors use the lentiviral approach for the RNAi study, this should not be too difficult.

Second, the expression, biochemical and pharmacological data in Fig. 3 appears fragmentary and unclear. The expression analysis shows that several GF receptors (FRGG1-3 /EGFR/Ntrk2) are expressed in NPSCs, but only FGFR1 is then presented in detail in the mutant contexts (3b). This data would be far more convincing with a systematic analysis of the expression of all GFRs in the mutants. Moreover, if only FGFR is a candidate, why is there EGF in the GF-mix in Fig. 3C. The pharmacological approach is too limited. Again, a systematic and complete analysis using several pharmacological interventions would be necessary to demonstrate specificity of the FGFR pathway. To my eyes this entire part is rather correlative and indirect.

Reviewer #2: In present study, Lin and co-authors studied the roles of major histocompatibility complex class I (MHC I) molecules, H2-K and H2-D in regulation of neural stem/progenitor cells and adult hippocampal neurogenesis. Specifically, they identified that H2-K, but not H2-D, governed adult neurogenesis by regulating cell cycle dynamics. Using hippocampal NSPCs culture combined with RNA-sequencing, they found that H2-K regulate cell proliferation through inhibiting FGFR-mediated signaling pathway. In general, it is a potential interesting study in the field. But there are still some major concerns that require further attention.

1) The in vivo neurogenesis has been performed on H2-K KO mice. However, the authors have not assessed whether H2-K mutation has developmental consequences on the DG cellular composition, which is highly possible if H2-K is a major actor in neurogenesis. In addition, H2-K deficiency led to increased proliferation of postnatal-derived NSPCs in vitro (Fig. 2B). Therefore, the defective adult hippocampal neurogenesis in H2-K KO mice could be a consequence of developmental defect, but is not specific in adult brain.

2) Although the bioinformatics analysis showed that the expression of H2-K was expressed in NSPCs and suggested its potential role in regulating adult hippocampal neurogenesis, it is still lacking of the in vivo expression pattern of H2K in adult hippocampal neurogenic niche to argue the specific role of H2K in NSPCs.

3) In adult K-/- mice, more generated new-born neurons (DCX+ cells) are observed, while there is an increased proliferation (Edu+ cells) in cultured K-/- NPSC, which suggested that the increased neurogenesis might be resulted by enhanced proliferation. It is necessary to perform short-term Edu/Brdu or use Ki67/MCM2 combined with cell type specific markers to evaluate proliferative status in vivo.

4) Both KD-/- and K-/- mice displayed increased neurogenesis in the adult hippocampus (Fig. 1 D and Fig. 1E, DCX and NeuN). However, it seems the number of Nestin+ cells in KD-/- mice is higher than that in K-/- mice (~3000 Nestin+ cells KD-/- mice [Fig.1E], while ~2000 Nestin+ cells K-/- mice [Fig. 1D]). Further comparison the number of Nestin+ cells between K-/- and KD-/- should be done to conclude whether the defective neurogenesis is due to altering Nestin+ cells in these two mutations.

Reviewer #3: In manuscript PBIOLOGY-D-20-02289, Lin et al. address the important issue of whether MHCI molecules regulate neural stem cell proliferation and neurogenesis. The authors first performed transcriptomic analyses of Neural Stem and Progenitors Cells (NSPCs) by analyzing a publicly available dataset of Nestin positive cells and their immediate progeny. Through this analysis, Lin et al found that the class I MHC H2-Kb was downregulated in NSCs that were more neurogenic in their transcriptomic signature, while H2-Db did not change significantly. The authors follow up with several of loss of function experiments with knockout and knockdown of the 2 Class I MHC's (H2Kb, H2Db) both separately and together, that implicate H2Kb in repressing the proliferation of NPSCs. This change in proliferation is described as an increase in DCX + and NeuN/Brdu+ cells in the DG of the adult hippocampus. In vitro experiments using primary NPSCs from both postnatal and adult mice showed that the % of EDU+ cells increases significantly when H2K is knocked out or knocked down with RNAi. Finally, transcriptomic analysis of NSPCs from H2K-/- mice showed a large difference in the transcriptomic signature compared to WT and H2D-/- cells. Specifically, cells that have elevated levels of H2K are less likely to have a cycling (proliferative) transcriptomic signature and FGFR1 mRNA is upregulated in K-/- NSPCs. They also found that an FGFR pharmacological inhibitor reduces the large increase in the % of Edu+ proliferating cells caused by H2K knoc down. The authors conclude that MHC I is required to regulate NSPC proliferation through inhibiting FGFR1 signaling.

Although these data are novel and address an important gap in our knowledge, there are several concerns that need to be addressed.

(1) The Western blot experiments should have been performed in the presence of phosphatase inhibitors to preserve the phosphorylation status of these proteins after lysis. There is also no quantification displayed, which is critical to assess any significant differences after

normalization of pERK to ERK and ERK and other proteins to GAPDH or Actin. Finally, the authors should indicate how many repeats of this biochemical experiment were performed; they are typically perfoemed in triplicate for quantification.

(2) It is unclear if the effects of MHCI on proliferation are truly specific and/or limited to H2K? Given that there is residual H2D mRNA expression in the H2D knockout, and the nominally higher levels of proliferative cells in the KD-/-, would it be more accurate to say that there remains a possibility of H2D having a role (although limited) in NSPC proliferation? One experiment to address this could be to express H2K and H2D In knockout K-/- KD-/- primary NSPCs, expecting to see a reduction in proliferation. Can H2D replace H2K to inhibit proliferation in this context?

(3) Data should be plotted by dot plot rather than bar graphs so that the variability can be more easily assessed.

(4) Figure 1: Panels D and E. The values for WT Dcx+ cells (~5K vs. ~10 K) and NeuN+BrDU+ cells (~600 vs. ~1200) are very different between the 2 experiments, whereas the control numbers of nestin+ cells are similar (~28K in both experiments). This raises the question of whether the WT used for each comparison are the appropriate controls, or whether the WT values are driving the result. The authors should clarify if the WT mice used for the comparisons to the single KO lines were littermates or a separate line and if the latter, they should indicate how many generations apart the lines are and include some data from littermates to increase confidence that the WT values are indeed the appropriate control comparison.

(5) More details about the samples used for the experiments should be included. When sample size is presented as n = 4, for example, the authors should explain whether there are 4 sections or 4 mice used, and whether the mice were from separate litters.

(6) On page 5, the authors state that "Together, these data suggest the influence of H2-Kb molecules in the adult hippocampal neurogenic niche is exerted during later stages of neurogenesis rather than the stem cell pool. " But, doesn't the increase in Edu+ cells in panel F, Figure 1, as well as other data in the paper indicate that H2-Kb regulates early stages of proliferation?

(7) Figure S4 is interpreted as demonstrating that there is no change in the % of neurons or astros in the cultures generated from WT, K-KO or D-KO mice. Yet, it looks like there might be a decrease in the # of cells from the D-KO, which would be important if true since a main conclusion from this paper is that H2-D does not play a role in adult neurogenesis. Including the actual data plotted (average value +/- sem, and the p-value) and increasing sample size for at least the controls in this particular experiment would determine if this trend is real. While it could be argued that increasing sample size may not be warranted due to power analysis, the actual variability in the experiment indicates that additional samples should be included to make the conclusion that H2-D does not affect proliferation.

(8) The approach used to determine whether cells express H2-K, or not, in Figure 2 seems potentially arbitrary. The authors should include a justification for selecting the threshold of 5 CPM as positive or negative for expression.

(9) On page 6, the authors state that "These bioinformatics data provide evidence that H2-Kb regulates NSPC proliferation in a cell-intrinsic manner, potentially by impacting the cell cycle." However, it is unclear why they conclude that this is cell-intrinsic.

(10) Figure 3, panel B. The graph appears to show a significant decrease in Fgfr1 expression in H2-D KO cells that is not indicated by an asterisk. This decrease would be important to note, if true, given the clear conclusion by the authors that H2-D does not regulate proliferation.

(11) Figure 3, panels D and E. Although the FGFR inhibitor largely rescues the sh-K-induced increase in proliferation in adult neurons, it is less effective in postnatal neurons. The authors should discuss potential reasons why this is the case.

(12) The authors interpret the result in Figure 3 as showing that "H2-Kb molecules negatively regulate NSPC proliferation by inhibiting FGFR-mediated signaling." Yet, the authors do not show this directly. To do so, they would need to increase H2Kb levels, show a decrease in FGFR signaling and in proliferation, and then rescue both by normalizing FGFR signaling.

Minor:

(1) Fig1. Legend- refers to S2, should be reference to S1.

(2) Fig2. Panel F X-axis should be labeled. J) Provide the number of cells in each group somewhere (H2-K1 positive, H2-K1 negative)

(3) Fig3. B) make clear in axis label that this is RNA

(4) Typo "ribosomal Proteign" in figure legend

Methods

(5) AG 99 is referenced in inhibitor experiments but it is unclear in what experiments it is used.

(6) Methods include references to western blot quantification, but none is presented in the paper

(7) Details are missing about how long after lentiviral injection for knockdown experiments BRDu was injected and animals perfused.

(8) C57 Bl6N(Tac) and Bl6J are both listed in methods. Which strain was a control for which experiments?

20 Apr 2021

Submitted filename: Lin_PLOSBIO_Response-to-Reviewers_041521.pdf

Click here for additional data file.

20 May 2021

Dear Dr Villeda,

Thank you for submitting your revised Short Report entitled "MHC CLASS I H2-KbNEGATIVELY REGULATES NEURAL PROGENITOR CELL PROLIFERATION BY INHIBITING FGFR SIGNALING" for publication in PLOS Biology. I have now obtained advice from the original reviewers and have discussed their comments with the Academic Editor.

Based on the reviews, we will probably accept this manuscript for publication, provided you satisfactorily address the data and other policy-related requests listed below my signature.

As you address these items, please take this last chance to review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the cover letter that accompanies your revised manuscript.

We expect to receive your revised manuscript within two weeks.

To submit your revision, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include the following:

-  a cover letter that should detail your responses to any editorial requests, if applicable, and whether changes have been made to the reference list

-  a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable)

-  a track-changes file indicating any changes that you have made to the manuscript.

NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:

https://journals.plos.org/plosbiology/s/supporting-information

*Published Peer Review History*

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*Early Version*

Please note that an uncorrected proof of your manuscript will be published online ahead of the final version, unless you opted out when submitting your manuscript. If, for any reason, you do not want an earlier version of your manuscript published online, uncheck the box. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please do not hesitate to contact me should you have any questions.

Sincerely,

Gabriel Gasque, Ph.D.,

Senior Editor,

ggasque@plos.org,

PLOS Biology

------------------------------------------------------------------------

TITLE:

To avoid confusion at copy-edit, please remove all caps from your title, reserving the capital letters for the words that need them: MHC class I H2-Kb, FGFR.

------------------------------------------------------------------------

COMPETING INTEREST:

Please include the following statement when declaring a competing interest: "LS is an associate editor for PLOS Biology. He was blinded to this manuscript and all related information in the journal's submission system and not involved at all in editorial discussions or the peer review process."

------------------------------------------------------------------------

ETHICS STATEMENT:

-- Please include the ID number of your experimental protocol approved by the University of California San Francisco IACUC.

-- Please include the specific national or international regulations/guidelines to which your animal care and use protocol adhered. Please note that institutional or accreditation organization guidelines (such as AAALAC) do not meet this requirement.

------------------------------------------------------------------------

DATA POLICY:

Thank you for providing the raw NSC RNA-sequencing data via ArrayExpress.

In addition, we need you to provide all individual quantitative observations that underlie the data summarized in the figures and results of your paper. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5

These data can be made available in one of the following forms:

1) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as 'Supporting Information' and are invariably referred to (in the manuscript, figure legends, and the Description field when uploading your files) using the following format verbatim: S1 Data, S2 Data, etc. Multiple panels of a single or even several figures can be included as multiple sheets in one excel file that is saved using exactly the following convention: S1_Data.xlsx (using an underscore).

2) Deposition in a publicly available repository. Please also provide the accession code or a reviewer link so that we may view your data before publication.

Regardless of the method selected, please ensure that you provide the individual numerical values that underlie the summary data displayed in the following figure panels: Figures 1ABEGHI, 2C-E, 3ABDEFGH, S1A, S2A-E, S3AB, S4A-D, S5BC, S6A-C, S7B, S8A-C, S8AC, and S10AB.

NOTE: the numerical data provided should include all replicates AND the way in which the plotted mean and errors were derived (it should not present only the mean/average values).

Please also ensure that each figure legend in your manuscript includes information on where the underlying data can be found and that your supplemental data file/s has/have a legend.

Please ensure that your Data Statement in the submission system accurately describes where your data can be found.

------------------------------------------------------------------------

BLOT AND GEL REPORTING REQUIREMENTS:

We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare and upload them now. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

------------------------------------------------------------------------

DATA NOT SHOWN?

Please note that per journal policy, we do not allow the mention of "data not shown", "personal communication", "manuscript in preparation" or other references to data that is not publicly available or contained within this manuscript. Please either remove mention of these data or provide figures presenting the results and the data underlying the figure(s).

------------------------------------------------------------------------

Reviewer remarks:

Reviewer #1: The authors followed my recommendations and provided convincing gain-of-function studies, that nicely complement the loss-of-function approach. Also, the strengthened the link between H2-K1 and Fgfr1 expression with new and convincing data. I have no further critique.

Reviewer #2: The authors have addressed all my concerns.

Reviewer #3: In their resubmission of PBIOLOGY-D-20-02289R1, the authors present a thorough response to all of the critiques and the manuscript is much improved. The only experiment they did not perform was to determine if FGFR overexpression rescues the decrease in proliferation caused by H2Kb overexpression. They have the constructs to perform this experiment, so it's unclear why they couldn't complete it. That being said, they do show strong evidence that H2-K1 and Fgfr1 signaling is linked and regulates NSPC proliferation. That is a novel and important finding and I am convinced that the manuscript is now strong enough for publication.

3 Jun 2021

Submitted filename: Lin_PLOSBIO_Response-to-Reviewers_060221_SV.pdf

Click here for additional data file.

4 Jun 2021

Dear Dr Villeda,

On behalf of my colleagues and the Academic Editor, Angélique Bordey, I am pleased to say that we can in principle offer to publish your Short Report "MHC class I H2-Kb negatively regulates neural progenitor cell proliferation by inhibiting FGFR signaling" in PLOS Biology, provided you address any remaining formatting and reporting issues:

>> Please ensure that each figure legend in your manuscript includes information on where the underlying data can be found (S1 Data)

>> Please ensure that your supplemental data file (S1 Data) has a legend.

>> Please ensure that your Data Statement in the submission system accurately describes where your data can be found, by including "All quantitative data can be found in the supporting material"

In addition, other formatting and reporting requests will be detailed in an email that will follow this letter and that you will usually receive within 2-3 business days, during which time no action is required from you. Please note that we will not be able to formally accept your manuscript and schedule it for publication until you have made the required changes.

Please take a minute to log into Editorial Manager at http://www.editorialmanager.com/pbiology/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with biologypress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

Thank you again for supporting Open Access publishing. We look forward to publishing your paper in PLOS Biology.

Sincerely,

Gabriel Gasque, Ph.D.

Senior Editor

PLOS Biology